Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Overview of benign lesions of the skin

Beth G Goldstein, MD
Adam O Goldstein, MD, MPH
Section Editor
Robert P Dellavalle, MD, PhD, MSPH
Deputy Editor
Rosamaria Corona, MD, DSc


Individuals may acquire a multitude of benign skin lesions over the course of a lifetime. Many of these lesions are easily visible, and patients often ask clinicians to confirm that new growths on the skin are benign.

Most benign skin lesions are diagnosed on the basis of clinical appearance and history. If the diagnosis of a lesion is uncertain, or if a lesion has exhibited unexpected changes in appearance or symptoms, a diagnostic procedure (eg, biopsy, excision) is indicated to confirm the diagnosis.

Benign lesions that are symptomatic or cosmetically bothersome can often be managed with simple procedures, such as cryotherapy, electrosurgery, or excision.

The clinical features, diagnosis, and treatment of some common acquired skin lesions will be discussed here. Malignant neoplasms of the skin are discussed separately. (See "Epidemiology, pathogenesis, and clinical features of basal cell carcinoma" and "Pathologic characteristics of melanoma" and "Clinical features and diagnosis of cutaneous squamous cell carcinoma (SCC)".)


Acrochordon (skin tag) — Acrochordons, commonly known as skin tags, are an outgrowth of normal skin (picture 1A-E). They appear as pedunculated lesions on narrow stalks. Skin tags occur in approximately 50 percent of adults; the risk increases with age [1]. Skin tags also appear with increased frequency during the second trimester of pregnancy and may regress postpartum [2].


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Sep 2016. | This topic last updated: Nov 11, 2015.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
  1. Banik R, Lubach D. Skin tags: localization and frequencies according to sex and age. Dermatologica 1987; 174:180.
  2. Winton GB, Lewis CW. Dermatoses of pregnancy. J Am Acad Dermatol 1982; 6:977.
  3. Boza JC, Trindade EN, Peruzzo J, et al. Skin manifestations of obesity: a comparative study. J Eur Acad Dermatol Venereol 2012; 26:1220.
  4. Ragunatha S, Anitha B, Inamadar AC, et al. Cutaneous disorders in 500 diabetic patients attending diabetic clinic. Indian J Dermatol 2011; 56:160.
  5. Senel E, Salmanoğlu M, Solmazgül E, Berçik İnal B. Acrochordons as a cutaneous sign of impaired carbohydrate metabolism, hyperlipidemia, liver enzyme abnormalities and hypertension: a case-control study. J Eur Acad Dermatol Venereol 2011.
  6. Shah R, Jindal A, Patel N. Acrochordons as a cutaneous sign of metabolic syndrome: a case-control study. Ann Med Health Sci Res 2014; 4:202.
  7. Akpinar F, Dervis E. Association between acrochordons and the components of metabolic syndrome. Eur J Dermatol 2012; 22:106.
  8. Peyrin-Biroulet L, Loftus EV Jr, Tremaine WJ, et al. Perianal Crohn's disease findings other than fistulas in a population-based cohort. Inflamm Bowel Dis 2012; 18:43.
  9. Toro JR, Wei MH, Glenn GM, et al. BHD mutations, clinical and molecular genetic investigations of Birt-Hogg-Dubé syndrome: a new series of 50 families and a review of published reports. J Med Genet 2008; 45:321.
  10. Palm MD, Altman JS. Topical hemostatic agents: a review. Dermatol Surg 2008; 34:431.
  11. Pusztaszeri M, Jaquet PY, Williamson C. Giant hemosiderotic dermatofibroma: a case report and review of the literature. Case Rep Dermatol 2011; 3:32.
  12. Requena L, Fariña MC, Fuente C, et al. Giant dermatofibroma. A little-known clinical variant of dermatofibroma. J Am Acad Dermatol 1994; 30:714.
  13. Mentzel T. Cutaneous mesenchymal tumours: an update. Pathology 2014; 46:149.
  14. Kaddu S, McMenamin ME, Fletcher CD. Atypical fibrous histiocytoma of the skin: clinicopathologic analysis of 59 cases with evidence of infrequent metastasis. Am J Surg Pathol 2002; 26:35.
  15. Luzar B, Calonje E. Cutaneous fibrohistiocytic tumours - an update. Histopathology 2010; 56:148.
  16. Lanigan SW, Robinson TW. Cryotherapy for dermatofibromas. Clin Exp Dermatol 1987; 12:121.
  17. Doyle LA, Fletcher CD. Metastasizing "benign" cutaneous fibrous histiocytoma: a clinicopathologic analysis of 16 cases. Am J Surg Pathol 2013; 37:484.
  18. Laskin WB, Miettinen M, Fetsch JF. Infantile digital fibroma/fibromatosis: a clinicopathologic and immunohistochemical study of 69 tumors from 57 patients with long-term follow-up. Am J Surg Pathol 2009; 33:1.
  19. Taylor HO, Gellis SE, Schmidt BA, et al. Infantile digital fibromatosis. Ann Plast Surg 2008; 61:472.
  20. Paloni G, Mattei I, Salmaso R, Cutrone M. Infantile digital fibromatosis. Arch Dis Child 2013; 98:308.
  21. Niamba P, Léauté-Labrèze C, Boralevi F, et al. Further documentation of spontaneous regression of infantile digital fibromatosis. Pediatr Dermatol 2007; 24:280.
  22. Campbell LB, Petrick MG. Mohs micrographic surgery for a problematic infantile digital fibroma. Dermatol Surg 2007; 33:385.
  23. Albertini JG, Welsch MJ, Conger LA, et al. Infantile digital fibroma treated with mohs micrographic surgery. Dermatol Surg 2002; 28:959.
  24. Hafner C, Vogt T. Seborrheic keratosis. J Dtsch Dermatol Ges 2008; 6:664.
  25. Li YH, Chen G, Dong XP, Chen HD. Detection of epidermodysplasia verruciformis-associated human papillomavirus DNA in nongenital seborrhoeic keratosis. Br J Dermatol 2004; 151:1060.
  26. Duperret EK, Oh SJ, McNeal A, et al. Activating FGFR3 mutations cause mild hyperplasia in human skin, but are insufficient to drive benign or malignant skin tumors. Cell Cycle 2014; 13:1551.
  27. Logié A, Dunois-Lardé C, Rosty C, et al. Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans. Hum Mol Genet 2005; 14:1153.
  28. Hafner C, Hartmann A, Real FX, et al. Spectrum of FGFR3 mutations in multiple intraindividual seborrheic keratoses. J Invest Dermatol 2007; 127:1883.
  29. Hafner C, López-Knowles E, Luis NM, et al. Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation pattern. Proc Natl Acad Sci U S A 2007; 104:13450.
  30. Chu CY, Yang CH, Chiu HC. Inflammation of seborrheic keratoses due to docetaxel treatment. Acta Derm Venereol 2001; 81:316.
  31. Patton T, Zirwas M, Nieland-Fisher N, Jukic D. Inflammation of seborrheic keratoses caused by cytarabine: a pseudo sign of Leser-Trelat. J Drugs Dermatol 2004; 3:565.
  32. Cascajo CD, Reichel M, Sánchez JL. Malignant neoplasms associated with seborrheic keratoses. An analysis of 54 cases. Am J Dermatopathol 1996; 18:278.
  33. Jee H, Lee NR, Ahn SK. Case of seborrheic keratosis with underlying basal cell carcinoma suggesting a collision tumor. J Dermatol 2013; 40:837.
  34. Defazio J, Zalaudek I, Busam KJ, et al. Association between melanocytic neoplasms and seborrheic keratosis: more than a coincidental collision? Dermatol Pract Concept 2012; 2:202a09.
  35. Birnie AJ, Varma S. A dermatoscopically diagnosed collision tumour: malignant melanoma arising within a seborrhoeic keratosis. Clin Exp Dermatol 2008; 33:512.
  36. Lim C. Seborrhoeic keratoses with associated lesions: a retrospective analysis of 85 lesions. Australas J Dermatol 2006; 47:109.
  37. Longo C, Moscarella E, Piana S, et al. Not all lesions with a verrucous surface are seborrheic keratoses. J Am Acad Dermatol 2014; 70:e121.
  38. Kim YK, Kim DY, Lee SJ, et al. Therapeutic efficacy of long-pulsed 755-nm alexandrite laser for seborrheic keratoses. J Eur Acad Dermatol Venereol 2014; 28:1007.
  39. Polder KD, Landau JM, Vergilis-Kalner IJ, et al. Laser eradication of pigmented lesions: a review. Dermatol Surg 2011; 37:572.
  40. Culbertson GR. 532-nm diode laser treatment of seborrheic keratoses with color enhancement. Dermatol Surg 2008; 34:525.
  41. Wood LD, Stucki JK, Hollenbeak CS, Miller JJ. Effectiveness of cryosurgery vs curettage in the treatment of seborrheic keratoses. JAMA Dermatol 2013; 149:108.
  42. Grimes PE, Arora S, Minus HR, Kenney JA Jr. Dermatosis papulosa nigra. Cutis 1983; 32:385.
  43. Garcia MS, Azari R, Eisen DB. Treatment of dermatosis papulosa nigra in 10 patients: a comparison trial of electrodesiccation, pulsed dye laser, and curettage. Dermatol Surg 2010; 36:1968.
  44. Taylor SC, Averyhart AN, Heath CR. Postprocedural wound-healing efficacy following removal of dermatosis papulosa nigra lesions in an African American population: a comparison of a skin protectant ointment and a topical antibiotic. J Am Acad Dermatol 2011; 64:S30.
  45. Mehrabi D, Leonhardt JM, Brodell RT. Removal of keratinous and pilar cysts with the punch incision technique: analysis of surgical outcomes. Dermatol Surg 2002; 28:673.
  46. Lee HE, Yang CH, Chen CH, et al. Comparison of the surgical outcomes of punch incision and elliptical excision in treating epidermal inclusion cysts: a prospective, randomized study. Dermatol Surg 2006; 32:520.
  47. Zuber TJ. Minimal excision technique for epidermoid (sebaceous) cysts. Am Fam Physician 2002; 65:1409.
  48. Klin B, Ashkenazi H. Sebaceous cyst excision with minimal surgery. Am Fam Physician 1990; 41:1746.
  49. Seidenari S, Pellacani G, Nasti S, et al. Hereditary trichilemmal cysts: a proposal for the assessment of diagnostic clinical criteria. Clin Genet 2013; 84:65.
  50. Torchia D, Vega J, Schachner LA. Eruptive vellus hair cysts: a systematic review. Am J Clin Dermatol 2012; 13:19.
  51. Saks K, Levitt JO. Tazarotene 0.1 percent cream fares better than erbium:YAG laser or incision and drainage in a patient with eruptive vellus hair cysts. Dermatol Online J 2006; 12:7.
  52. Kaya TI, Tataroglu C, Tursen U, Ikizoglu G. Eruptive vellus hair cysts: an effective extraction technique for treatment and diagnosis. J Eur Acad Dermatol Venereol 2006; 20:264.
  53. Fernández-Torres R, Del Pozo J, Castiñeiras I, et al. Treatment of multiple eruptive vellus hair cysts with carbon dioxide laser vaporization and manual lateral pressure. Clin Exp Dermatol 2009; 34:e716.
  54. Chandawarkar RY, Rodriguez P, Roussalis J, Tantri MD. Minimal-scar segmental extraction of lipomas: study of 122 consecutive procedures. Dermatol Surg 2005; 31:59.
  55. Wilhelmi BJ, Blackwell SJ, Mancoll JS, Phillips LG. Another indication for liposuction: small facial lipomas. Plast Reconstr Surg 1999; 103:1864.
  56. Rotunda AM, Ablon G, Kolodney MS. Lipomas treated with subcutaneous deoxycholate injections. J Am Acad Dermatol 2005; 53:973.
  57. Amber KT, Ovadia S, Camacho I. Injection therapy for the management of superficial subcutaneous lipomas. J Clin Aesthet Dermatol 2014; 7:46.
  58. Dank JP, Colven R. Protease inhibitor-associated angiolipomatosis. J Am Acad Dermatol 2000; 42:129.
  59. Kaneko T, Tokushige H, Kimura N, et al. The treatment of multiple angiolipomas by liposuction surgery. J Dermatol Surg Oncol 1994; 20:690.
  60. Kanter WR, Wolfort FG. Multiple familial angiolipomatosis: treatment of liposuction. Ann Plast Surg 1988; 20:277.
  61. Gombos Z, Zhang PJ. Glomus tumor. Arch Pathol Lab Med 2008; 132:1448.
  62. Brems H, Park C, Maertens O, et al. Glomus tumors in neurofibromatosis type 1: genetic, functional, and clinical evidence of a novel association. Cancer Res 2009; 69:7393.
  63. Stewart DR, Sloan JL, Yao L, et al. Diagnosis, management, and complications of glomus tumours of the digits in neurofibromatosis type 1. J Med Genet 2010; 47:525.
  64. Kumar MG, Emnett RJ, Bayliss SJ, Gutmann DH. Glomus tumors in individuals with neurofibromatosis type 1. J Am Acad Dermatol 2014; 71:44.
  65. Baek HJ, Lee SJ, Cho KH, et al. Subungual tumors: clinicopathologic correlation with US and MR imaging findings. Radiographics 2010; 30:1621.
  66. Thompson SC, Jolley D, Marks R. Reduction of solar keratoses by regular sunscreen use. N Engl J Med 1993; 329:1147.
  67. Hexsel D, Hexsel C, Porto MD, Siega C. Triple combination as adjuvant to cryotherapy in the treatment of solar lentigines: investigator-blinded, randomized clinical trial. J Eur Acad Dermatol Venereol 2015; 29:128.
  68. Wagner G, Liefeith J, Sachse MM. Clinical appearance, differential diagnoses and therapeutical options of chondrodermatitis nodularis chronica helicis Winkler. J Dtsch Dermatol Ges 2011; 9:287.
  69. Magro CM, Dyrsen ME. The use of C3d and C4d immunohistochemistry on formalin-fixed tissue as a diagnostic adjunct in the assessment of inflammatory skin disease. J Am Acad Dermatol 2008; 59:822.
  70. Kuen-Spiegl M, Ratzinger G, Sepp N, Fritsch P. Chondrodermatitis nodularis chronica helicis - a conservative therapeutic approach by decompression. J Dtsch Dermatol Ges 2011; 9:292.
  71. Sanu A, Koppana R, Snow DG. Management of chondrodermatitis nodularis chronica helicis using a 'doughnut pillow'. J Laryngol Otol 2007; 121:1096.
  72. Moncrieff M, Sassoon EM. Effective treatment of chondrodermatitis nodularis chronica helicis using a conservative approach. Br J Dermatol 2004; 150:892.
  73. Timoney N, Davison PM. Management of chondrodermatitis helicis by protective padding: a series of 12 cases and a review of the literature. Br J Plast Surg 2002; 55:387.
  74. Cox NH, Denham PF. Intralesional triamcinolone for chondrodermatitis nodularis: a follow-up study of 60 patients. Br J Dermatol 2002; 146:712.
  75. Gilaberte Y, Frias MP, Pérez-Lorenz JB. Chondrodermatitis nodularis helicis successfully treated with photodynamic therapy. Arch Dermatol 2010; 146:1080.
  76. Pellegrino M, Taddeucci P, Mei S, et al. Chondrodermatitis nodularis chronica helicis and photodynamic therapy: a new therapeutic option? Dermatol Ther 2011; 24:144.
  77. Flynn V, Chisholm C, Grimwood R. Topical nitroglycerin: a promising treatment option for chondrodermatitis nodularis helicis. J Am Acad Dermatol 2011; 65:531.
  78. Garrido Colmenero C, Martínez García E, Blasco Morente G, Tercedor Sánchez J. Nitroglycerin patch for the treatment of chondrodermatitis nodularis helicis: a new therapeutic option. Dermatol Ther 2014; 27:278.
  79. Lawrence CM. The treatment of chondrodermatitis nodularis with cartilage removal alone. Arch Dermatol 1991; 127:530.
  80. de Ru JA, Lohuis PJ, Saleh HA, Vuyk HD. Treatment of chondrodermatitis nodularis with removal of the underlying cartilage alone: retrospective analysis of experience in 37 lesions. J Laryngol Otol 2002; 116:677.
  81. Taylor MB. Chondrodermatitis nodularis chronica helicis. Successful treatment with the carbon dioxide laser. J Dermatol Surg Oncol 1991; 17:862.
  82. Coldiron BM. The surgical management of chondrodermatitis nodularis chronica helicis. J Dermatol Surg Oncol 1991; 17:902.
  83. Kromann N, Høyer H, Reymann F. Chondrodermatitis nodularis chronica helicis treated with curettage and electrocauterization: follow-up of a 15-year material. Acta Derm Venereol 1983; 63:85.
  84. Hussain W, Chalmers RJ. Simplified surgical treatment of chondrodermatitis nodularis by cartilage trimming and sutureless skin closure. Br J Dermatol 2009; 160:116.
  85. Feldman AL, Manstein CH, Manstein ME, Czulewicz A. Chondrodermatitis nodularis auricularis: a new name for an old disease. Plast Reconstr Surg 2009; 123:25e.
  86. Jay H, Borek C. Treatment of a venous-lake angioma with intense pulsed light. Lancet 1998; 351:112.
Topic Outline